Published 2 days ago • loading... • Updated 17 hours ago

Roche signs biggest-ever obesity drug deal

Harbour BioMed has launched �lanc� Therapeutics, focusing on innovative therapies for obesity treatment.
�Lanc� aims to develop bispecific antibody programs that enhance weight loss while preserving lean muscle mass.
According to Jingsong Wang, �lanc�'s approach may redefine obesity therapeutics by targeting multiple pathways, optimizing weight loss efficacy and improving long-term outcomes.
Obesity currently affects nearly one billion people globally, which is linked to serious health issues.

Insights by Ground AI

Does this summary seem wrong?

59 Articles

All

Left

Center

Right

CBC News

Dad of 7-year-old with rare condition 'very scared' as Ontario family can't afford $300K annual treatment

Cena Hermus, 7, was two years old when she was diagnosed with a rare, life-threatening disorder that causes severe obesity. The medication she needs costs around $300,000 annually, something the family, who now live in Hamilton, say she can't afford.

17 hours ago·Canada

Read Full Article

Investor's Business Daily

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.

1 day ago

Read Full Article

News Medical

Waist-to-height ratio more accurate than BMI for detecting childhood obesity

Body mass index (BMI) was almost three times more likely to classify children as overweight than waist circumference-to-height ratio, according to a new study.

1 day ago·United States

Read Full Article

SWI swissinfo.ch

Swiss pharma giant Roche partners with Zealand Pharma on new obesity treatment

Roche announced that it has struck an exclusive deal with Denmark's Zealand Pharma to develop and market petrelintide, a new treatment for obesity.

1 day ago·Bern, Switzerland

Read Full Article

Fortune

Roche, Zealand Pharma in $5.3 billion pact for obesity drugs

Roche Holding licensed a new weight-loss drug from Zealand Pharma, bolstering the drugmaker’s effort to get into a hot market dominated by Novo Nordisk and Eli Lilly & Co.

2 days ago·New York, United States

Roche shares pop 5% on $5.3 billion obesity drug deal with Zealand Pharma

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

2 days ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year